Venus Remedies has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs. With this, the company has secured 511 marketing approvals for its oncology products across 66 countrles.
Oncology drugs constitute the largest proportion of the Serbian pharma market (projected to reach $397.40 million in 2023), where Venus Remedies has secured five marketing approvals, all ln the oncology space. The high prevalence of breast cancer, ovarian cancer, pancreatic cancer and cancers of the lung and intestine is a key driver of the global oncology market, which was valued at $286.04 billion in 2021 and is projected to reach $536.01 billion by 2029 at a compounded annual growth rate (CAGR) of 8.2 per cent from 2021 to 2030.
Aditi K Chaudhary, President, International Business, Venus Remedies, said, “We have more than 40 marketing authorisations in South Eastern Europe and Balkan region, including nine for oncology drugs, and we are now banking on the product registrations for gemcitabine and docetaxel from Serbia to pave the way for faster approvals for cancer medicines in other countries in this part of Europe.”
Venus Remedies secured a marketing authorisation for gemcitabine from Bosnla a few months ago, which was followed by marketing approvals for docetaxel from Georgia and two other key cancer drugs from Moldova.